These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 17499194)
1. Evaluation of anti-tumor effects of tumor cell lysate enriched by HSP-70 against fibrosarcoma tumor in BALB/c mice. Hashemi SM; Hassan ZM; Soudi S; Ghazanfari T; Kheirandish M; Shahabi S Int Immunopharmacol; 2007 Jul; 7(7):920-7. PubMed ID: 17499194 [TBL] [Abstract][Full Text] [Related]
2. The effect of vaccination with the lysate of heat-shocked tumor cells on nitric oxide production in BALB/c mice with fibrosarcoma tumor. Hashemi SM; Hassan ZM; Soudi S; Shahabi S Cell Biol Int; 2008 Jul; 32(7):835-40. PubMed ID: 18455932 [TBL] [Abstract][Full Text] [Related]
3. Enhancement of Th1 immune response by CD8alpha(+) dendritic cells loaded with heat shock proteins enriched tumor extract in tumor-bearing mice. Azadmehr A; Pourfathollah AA; Amirghofran Z; Hassan ZM; Moazzeni SM Cell Immunol; 2009; 260(1):28-32. PubMed ID: 19712929 [TBL] [Abstract][Full Text] [Related]
4. Naloxone can improve the anti-tumor immunity by reducing the CD4+CD25+Foxp3+ regulatory T cells in BALB/c mice. Molla Hassan AT; Hassan ZM; Moazzeni SM; Mostafaie A; Shahabi S; Ebtekar M; Hashemi SM Int Immunopharmacol; 2009 Nov; 9(12):1381-6. PubMed ID: 19706340 [TBL] [Abstract][Full Text] [Related]
5. Long acting propranolol and HSP-70 rich tumor lysate reduce tumor growth and enhance immune response against fibrosarcoma in Balb/c mice. Khalili A; Hassan ZM; Shahabi S; Pourfathollah AA; Ostad SN; Noori S; Mahdavi M; Haybar H; Langroudi L Iran J Immunol; 2013 Jun; 10(2):70-82. PubMed ID: 23811546 [TBL] [Abstract][Full Text] [Related]
6. Autoreactive and heat shock protein 60-recognizing CD4+ T-cells show antitumor activity against syngeneic fibrosarcoma. Harada M; Matsuzaki G; Yoshikai Y; Kobayashi N; Kurosawa S; Takimoto H; Nomoto K Cancer Res; 1993 Jan; 53(1):106-11. PubMed ID: 8093229 [TBL] [Abstract][Full Text] [Related]
7. In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma. Wu A; Oh S; Gharagozlou S; Vedi RN; Ericson K; Low WC; Chen W; Ohlfest JR J Immunother; 2007; 30(8):789-97. PubMed ID: 18049330 [TBL] [Abstract][Full Text] [Related]
9. Mode-of-action, efficacy, and safety of a homologous multi-epitope vaccine in a murine model for adjuvant treatment of renal cell carcinoma. Doehn C; Esser N; Pauels HG; Kiessig ST; Stelljes M; Grossmann A; Jocham D; Drevs J Eur Urol; 2009 Jul; 56(1):123-31. PubMed ID: 18550267 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of anti-cancer and immunomodulatory effects of carnosol in a Balb/c WEHI-164 fibrosarcoma model. Rahnama M; Mahmoudi M; Zamani Taghizadeh Rabe S; Balali-Mood M; Karimi G; Tabasi N; Riahi-Zanjani B J Immunotoxicol; 2015; 12(3):231-8. PubMed ID: 25027673 [TBL] [Abstract][Full Text] [Related]
11. Vaccination with a DNA vaccine based on human PSCA and HSP70 adjuvant enhances the antigen-specific CD8+ T-cell response and inhibits the PSCA+ tumors growth in mice. Zhang X; Yu C; Zhao J; Fu L; Yi S; Liu S; Yu T; Chen W J Gene Med; 2007 Aug; 9(8):715-26. PubMed ID: 17595048 [TBL] [Abstract][Full Text] [Related]
12. Synergistic effects between Staphylococcal enterotoxin type B and Monophosphoryl lipid A against mouse fibrosarcoma. Imani Fooladi AA; Sattari M; Reza Nourani M J BUON; 2010; 15(2):340-7. PubMed ID: 20658733 [TBL] [Abstract][Full Text] [Related]
13. Cationic lipid:bacterial DNA complexes elicit adaptive cellular immunity in murine intraperitoneal tumor models. Lanuti M; Rudginsky S; Force SD; Lambright ES; Siders WM; Chang MY; Amin KM; Kaiser LR; Scheule RK; Albelda SM Cancer Res; 2000 Jun; 60(11):2955-63. PubMed ID: 10850443 [TBL] [Abstract][Full Text] [Related]
14. Characterization of anti-tumor immunity derived from the inoculation of myeloma cells secreting the fusion protein RM4/IFN-tau. Qi Y; Moyana T; Chen Y; Xiang J Hum Antibodies Hybridomas; 1996; 7(1):21-6. PubMed ID: 8886833 [TBL] [Abstract][Full Text] [Related]
15. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies. Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962 [TBL] [Abstract][Full Text] [Related]
16. Screening of cytokines to enhance vaccine effects of heat shock protein 70-rich tumor cell lysate. Ito A; Fujioka M; Tanaka K; Kobayashi T; Honda H J Biosci Bioeng; 2005 Jul; 100(1):36-42. PubMed ID: 16233848 [TBL] [Abstract][Full Text] [Related]
17. HPV16E7 tumor antigen modified by KDEL sequence induce specific cytotoxic T lymphocytes-dependent antitumor immunity. Yin R; Zheng W; Hao F; Yang XC; Zhong BY; Li QJ J Dermatol Sci; 2009 Aug; 55(2):116-22. PubMed ID: 19500947 [TBL] [Abstract][Full Text] [Related]
18. Combinations of tumor-specific CD8+ CTLs and anti-CD25 mAb provide improved immunotherapy. Ohmura Y; Yoshikawa K; Saga S; Ueda R; Kazaoka Y; Yamada S Oncol Rep; 2008 May; 19(5):1265-70. PubMed ID: 18425386 [TBL] [Abstract][Full Text] [Related]
19. Experimental study of specific immunotherapy induced by H22 autologous tumor as whole tumor cell vaccine. Yang W; Guo C; Liu QG; Pan C Biomed Pharmacother; 2009 Jul; 63(6):404-8. PubMed ID: 18849136 [TBL] [Abstract][Full Text] [Related]
20. Therapy-induced antitumor vaccination by targeting tumor necrosis factor alpha to tumor vessels in combination with melphalan. Mortara L; Balza E; Sassi F; Castellani P; Carnemolla B; De Lerma Barbaro A; Fossati S; Tosi G; Accolla RS; Borsi L Eur J Immunol; 2007 Dec; 37(12):3381-92. PubMed ID: 18022863 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]